Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 1.61
XOMA's Cash to Debt is ranked higher than
59% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. XOMA: 1.61 )
XOMA' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: 1.61

Equity to Asset -0.26
XOMA's Equity to Asset is ranked higher than
50% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. XOMA: -0.26 )
XOMA' s 10-Year Equity to Asset Range
Min: -0.77   Max: 0.82
Current: -0.26

-0.77
0.82
F-Score: 3
Z-Score: -21.44
M-Score: -4.00
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -289.37
XOMA's Operating margin (%) is ranked higher than
63% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -78.59 vs. XOMA: -289.37 )
XOMA' s 10-Year Operating margin (%) Range
Min: -2191.67   Max: 13.17
Current: -289.37

-2191.67
13.17
Net-margin (%) -307.85
XOMA's Net-margin (%) is ranked higher than
63% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -70.38 vs. XOMA: -307.85 )
XOMA' s 10-Year Net-margin (%) Range
Min: -2153.94   Max: 14.89
Current: -307.85

-2153.94
14.89
ROE (%) -1419.43
XOMA's ROE (%) is ranked lower than
53% of the 1134 Companies
in the Global Biotechnology industry.

( Industry Median: -34.93 vs. XOMA: -1419.43 )
XOMA' s 10-Year ROE (%) Range
Min: -2950.04   Max: -47.95
Current: -1419.43

-2950.04
-47.95
ROA (%) -84.25
XOMA's ROA (%) is ranked higher than
55% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. XOMA: -84.25 )
XOMA' s 10-Year ROA (%) Range
Min: -139.63   Max: 4.68
Current: -84.25

-139.63
4.68
ROC (Joel Greenblatt) (%) -1292.57
XOMA's ROC (Joel Greenblatt) (%) is ranked higher than
66% of the 1212 Companies
in the Global Biotechnology industry.

( Industry Median: -442.83 vs. XOMA: -1292.57 )
XOMA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1189.47   Max: 53.99
Current: -1292.57

-1189.47
53.99
Revenue Growth (%) -39.00
XOMA's Revenue Growth (%) is ranked higher than
62% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: -1.90 vs. XOMA: -39.00 )
XOMA' s 10-Year Revenue Growth (%) Range
Min: -60.9   Max: 147.7
Current: -39

-60.9
147.7
EBITDA Growth (%) -26.40
XOMA's EBITDA Growth (%) is ranked higher than
61% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -4.60 vs. XOMA: -26.40 )
XOMA' s 10-Year EBITDA Growth (%) Range
Min: -38.3   Max: 31.3
Current: -26.4

-38.3
31.3
EPS Growth (%) -27.10
XOMA's EPS Growth (%) is ranked higher than
64% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. XOMA: -27.10 )
XOMA' s 10-Year EPS Growth (%) Range
Min: -53   Max: 36.5
Current: -27.1

-53
36.5
» XOMA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

XOMA Guru Trades in Q4 2013

Paul Tudor Jones 20,425 sh (New)
» More
Q1 2014

XOMA Guru Trades in Q1 2014

John Burbank 49,774 sh (New)
Louis Moore Bacon 75,000 sh (New)
Paul Tudor Jones 33,233 sh (+62.71%)
» More
Q2 2014

XOMA Guru Trades in Q2 2014

Louis Moore Bacon 75,000 sh (unchged)
John Burbank Sold Out
Paul Tudor Jones Sold Out
» More
Q3 2014

XOMA Guru Trades in Q3 2014

Louis Moore Bacon Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with XOMA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2014-06-30 Sold Out 0.01%$3.43 - $5.27 $ 4.596%0
John Burbank 2014-03-31 New Buy0.01%$4.96 - $9.44 $ 4.59-37%49774
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 18.36
XOMA's P/S is ranked higher than
77% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 32.74 vs. XOMA: 18.36 )
XOMA' s 10-Year P/S Range
Min: 0.04   Max: 21.2
Current: 18.36

0.04
21.2
Current Ratio 1.78
XOMA's Current Ratio is ranked higher than
58% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. XOMA: 1.78 )
XOMA' s 10-Year Current Ratio Range
Min: 0.63   Max: 6.65
Current: 1.78

0.63
6.65
Quick Ratio 1.78
XOMA's Quick Ratio is ranked higher than
60% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. XOMA: 1.78 )
XOMA' s 10-Year Quick Ratio Range
Min: 0.63   Max: 6.65
Current: 1.78

0.63
6.65

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 21.85
XOMA's Price/Median PS Value is ranked higher than
70% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. XOMA: 21.85 )
XOMA' s 10-Year Price/Median PS Value Range
Min: 0.06   Max: 341.91
Current: 21.85

0.06
341.91
Earnings Yield (Greenblatt) -16.60
XOMA's Earnings Yield (Greenblatt) is ranked higher than
60% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -6.40 vs. XOMA: -16.60 )
XOMA' s 10-Year Earnings Yield (Greenblatt) Range
Min: 208.5   Max: 151510.8
Current: -16.6

208.5
151510.8
Forward Rate of Return (Yacktman) -16.45
XOMA's Forward Rate of Return (Yacktman) is ranked higher than
69% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: -6.41 vs. XOMA: -16.45 )
XOMA' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -1720.5   Max: -16.4
Current: -16.45

-1720.5
-16.4

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:X0M.Germany
XOMA Corp was incorporated in Delaware on 1981 and became a Bermuda-exempted company in December 1998. The Company is a biotechnology company, which is engaged in the discovery, development and manufacture of therapeutic antibodies and other agents designed to treat inflammatory, autoimmune, infectious and oncological diseases. The Company builds a product pipeline that includes multiple proprietary and collaborative development programs. Its proprietary preclinical pipeline includes classes of antibodies that activate, sensitize, or deactivate the insulin receptor in vivo, that have been named as XMet. This portfolio of antibodies represents potential new therapeutic approaches to the treatment of diabetes and several diseases that involve insulin, which it believe may be orphan drug opportunities. Its main product candidate is XOMA 052, a potent monoclonal antibody with the potential to improve the treatment of patients with a number of diseases in which inflammation is either the cause or plays a considerable role. The company receives royalties on approved products, RAPTIVA, which is marketed globally for the treatment of chronic moderate-to-severe plaque psoriasis, LUCENTIS, which is marketed globally for the treatment of neovascular (wet) age-related macular degeneration, and the Company no longer receives royalties on sales of CIMZIA. XOMA has granted more than 60 licenses to biotechnology and pharmaceutical companies to use the Company's patented and proprietary technologies relating to bacterial expression of recombinant pharmaceutical products.
» More Articles for XOMA

Headlines

Articles On GuruFocus.com
comment on XOMA Mar 06 2013 
XOMA Ltd. Reports Operating Results (10-K) Mar 10 2011 
XOMA Ltd. Reports Operating Results (10-K/A) Dec 27 2010 
XOMA Ltd. Reports Operating Results (10-Q/A) Nov 12 2010 
XOMA Ltd. Reports Operating Results (10-Q) May 06 2010 
XOMA Ltd. Reports Operating Results (10-Q) Aug 06 2009 
XOMA Ltd. Reports Operating Results (10-Q) May 07 2009 

More From Other Websites
XOMA Corp Worth Watching: Stock Moves 10.3% Higher Nov 21 2014
Trade-Ideas: XOMA (XOMA) Is Today's Strong On High Relative Volume Stock Nov 20 2014
XOMA CORP Financials Nov 14 2014
XOMA to Present at Upcoming Investor Conferences Nov 10 2014
XOMA to Present at Upcoming Investor Conferences Nov 10 2014
XOMA Corp Volatile Amid Differing Analyst Reports Nov 10 2014
10-Q for XOMA Corp. Nov 08 2014
XOMA (XOMA) Stock: Weak On High Volume Today Nov 07 2014
Xoma misses Street 3Q forecasts Nov 06 2014
Xoma misses Street 3Q forecasts Nov 06 2014
XOMA Corp Earnings Call scheduled for 4:30 pm ET today Nov 06 2014
XOMA CORP Files SEC form 10-Q, Quarterly Report Nov 06 2014
XOMA Highlights Recent Achievements and Reports Financial Results for the Third Quarter of 2014 Nov 06 2014
Q3 2014 XOMA Corp Earnings Release - After Market Close Nov 06 2014
Should You Buy XOMA Corporation (XOMA) Ahead of Earnings? Nov 05 2014
XOMA Initiates Pivotal Phase 3 Gevokizumab Study in Patients With Pyoderma Gangrenosum Nov 04 2014
XOMA Initiates Pivotal Phase 3 Gevokizumab Study in Patients With Pyoderma Gangrenosum Nov 04 2014
XOMA to Announce Third Quarter 2014 Financial Results and Host Webcast on November 6 Oct 27 2014
XOMA to Announce Third Quarter 2014 Financial Results and Host Webcast on November 6 Oct 27 2014
XOMA Starts Phase I Study on XOMA 358 for Hyperinsulinism Oct 10 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK